# Forensic Dossier: Study Forensics: APJ agonist as pharmacological exercise mimetic

**Run ID:** `praxis_study-forensics-030_Claude_Haiku_165c7d`  
**Task:** study-forensics-030 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-07T07:56:44.342935+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** preclinical_to_therapeutic_leap  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** decorative_uncertainty, wrong_answer
**Forensic flags:** 2
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.7/8 | 4.8/8 | 4.8/6 | 3.6/6 | 5.2/6 | 5.6/8 | 8.0/8 | 3.0/10 | 8.5/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `overclaim` [x] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, conclusion_exceeds_results
**Extra Findings:** cautious_scope_control, none_or_minor, unsupported_generalization, decorative_uncertainty, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :white_check_mark: (1 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "overclaim"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "overclaim"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "overclaim"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: No match (got: overclaim)

**Support Strength:** 1.2/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 4.8/8
  - (+) `steps[2]`: "Recognized that while the preclinical results appear positive (HbA1c reduction, weight loss, muscle preservation, cardia"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[0]`: "The study is preclinical (mouse models) based on the text describing 'obese and diabetic mice' and 'heart-failure model'"
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.6/6
  - (+) `uncertainties[0]`: "Whether the company's full report includes appropriate caveats about preclinical-to-clinical translation (this summary m"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.82"
    _Stated confidence level_
  - (-) `uncertainties[0]`: "Whether the company's full report includes appropriate caveats about preclinical-to-clinical translation (this summary m"
    _Listed but never addressed in reasoning_
  - Note: 5 uncertainties (5 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 5.2/6
  - (+) `alternative_hypotheses[1]`: "This could be 'solid' if interpreted charitably as a preclinical report with appropriate caveats about translation (thou"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 1/2 include rejection reasoning

**Self Monitoring Quality:** 5.6/8
  - (+) `self_check[4]`: "Is the 'exercise mimetic' claim actually unsupported? Yes — the text provides no evidence that APJ activation reproduces"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 0 deep, 5 arithmetic, 0 fluff

**Mechanism Quality:** 3.0/10
  - (+) `(mechanism analysis)`: "Assessed whether the mechanism is established: APJ pathway activation in mice shows metabolic benefits, but whether this"
    _Mechanism description_
  - Note: Describes mechanism but does not name concept

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.66, 579 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "overclaim"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'mechanism_vs_evidence', detected 'overclaim'
  - `final_answer`: "overclaim"
  - _Impacts: correctness_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Whether the company's full report includes appropriate cavea...' is listed but not addressed
  - `uncertainties[0]`: "Whether the company's full report includes appropriate caveats about preclinical-to-clinical transla"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/23 content words)
  - `key_claims[0]`: "The core overclaim: A drug that works in mouse models of obesity, diabetes, and heart failure is pre"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/16 content words)
  - `key_claims[1]`: "Mechanism extrapolation: APJ pathway activation improves metabolic and cardiac outcomes in mice, but"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/12 content words)
  - `key_claims[2]`: "Premature translation: The company is 'preparing to translate' based on preclinical efficacy, but th"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/12 content words)
  - `key_claims[3]`: "Combination therapy claim: Synergy with incretin therapy is shown in mice; generalizability to human"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "This could be classified as 'mechanism_vs_evidence' if the emphasis is on applying a mouse mechanism"
- **[NOTE]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Causal mechanism described but underlying concept not named
  - `final_answer`: "overclaim"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 14649ms

**Final Answer:** overclaim

**Confidence:** 0.82

**Assumptions:**
- The study is preclinical (mouse models) based on the text describing 'obese and diabetic mice' and 'heart-failure model'
- The company is making forward-looking claims about human translation based on animal efficacy
- No human data are presented in this summary
- The mechanism (APJ pathway activation) is being extrapolated from rodent physiology to humans
- The term 'exercise hormone' system is being used descriptively, not as a proven functional equivalence

**Reasoning Steps:**
1. Identified that all efficacy data are from mouse models, not humans
2. Noted the company claims the drug 'could serve as a pharmacological exercise mimetic' — this is a functional claim about human physiology based on rodent data
3. Recognized that while the preclinical results appear positive (HbA1c reduction, weight loss, muscle preservation, cardiac improvements), the leap to 'exercise mimetic' in humans is unsupported
4. Assessed whether the mechanism is established: APJ pathway activation in mice shows metabolic benefits, but whether this translates to human exercise physiology is not demonstrated
5. Evaluated the combination therapy claim: synergy with incretin therapy is shown in mice, but generalizability to humans is unknown
6. Checked for confounders: mouse models of obesity/diabetes and heart failure are simplified systems; human disease is more complex
7. Assessed decorative uncertainty: the text says 'preparing to translate' but frames the mechanism as already established ('could serve as'), which is premature

**Key Claims:**
- The core overclaim: A drug that works in mouse models of obesity, diabetes, and heart failure is presented as a candidate 'pharmacological exercise mimetic' for humans without human data or direct evidence that it mimics exercise physiology
- Mechanism extrapolation: APJ pathway activation improves metabolic and cardiac outcomes in mice, but whether this pathway is the rate-limiting step in human exercise response is not established
- Premature translation: The company is 'preparing to translate' based on preclinical efficacy, but the functional equivalence to exercise has not been demonstrated
- Combination therapy claim: Synergy with incretin therapy is shown in mice; generalizability to humans is assumed, not proven

**Alternative Hypotheses:**
- This could be classified as 'mechanism_vs_evidence' if the emphasis is on applying a mouse mechanism to human exercise physiology without evidence
- This could be 'solid' if interpreted charitably as a preclinical report with appropriate caveats about translation (though the text does not provide such caveats)

**Uncertainties:**
- Whether the company's full report includes appropriate caveats about preclinical-to-clinical translation (this summary may omit them)
- Whether 'exercise hormone' is the company's language or the reporter's interpretation
- The specific design of the mouse studies (e.g., were controls appropriate, were doses optimized, was blinding used?)
- Whether the combination therapy results are additive or synergistic, and what the mechanism of synergy is
- Whether the cardiac benefits are direct APJ effects or secondary to metabolic improvement

**Self-Verification:**
- Did I overstate the problems? No — the text explicitly claims the drug 'could serve as a pharmacological exercise mimetic' based only on mouse data. This is a genuine overclaim.
- Did I miss that this is just a preclinical report? No — I acknowledged that and noted the leap from preclinical to functional claim is the problem.
- Did I assume the study is poorly designed? No — I noted that the preclinical results appear positive; the issue is the scope of the claim, not the quality of the mouse work.
- Did I conflate 'preclinical' with 'bad'? No — preclinical studies are valuable, but claims about human physiology require human evidence.
- Is the 'exercise mimetic' claim actually unsupported? Yes — the text provides no evidence that APJ activation reproduces the physiological effects of exercise in humans, only that it improves metabolic markers in mice.

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.7/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.6/6 `######....`
- Alternative Hypothesis Quality: 5.2/6 `########..`
- Self Monitoring Quality: 5.6/8 `#######...`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 3.0/10 `###.......`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.7/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.6/6)
- Alternative Hypothesis Quality: Claude Haiku (5.2/6)
- Self Monitoring Quality: Claude Haiku (5.6/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (3.0/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 14.6s | 40.0/100 | 2.7 |

Failure modes observed: decorative_uncertainty, wrong_answer.
